Viking Therapeutics has signed a long-term, $150 million strategic partnership with CordenPharma to support the development and commercialization of VK2735, its dual GLP-1/GIP receptor agonist for ...

VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is being developed in both oral and subcutaneous ...

One of the most promising GLP-1 contenders is VK2735, a dual GLP-1/GIP receptor agonist similar to tirzepatide, owned by Viking Therapeutics Inc. (NASDAQ: VKTX). Oppenheimer Sets a $138 Price ...

CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment ...